Use of Connected Pen as a Diagnostic Tool to Evaluate Missed Bolus Dosing Behavior in People with Type 1 and Type 2 Diabetes
| العنوان: | Use of Connected Pen as a Diagnostic Tool to Evaluate Missed Bolus Dosing Behavior in People with Type 1 and Type 2 Diabetes |
|---|---|
| المؤلفون: | Howard Wolpert, Eric S. Meadows, Stephanie Edwards, Xuanyao He, Wenjie Wang, Jennal Johnson, David Price, Jiat-Ling Poon, William H. Polonsky |
| المصدر: | Diabetes Technology & Therapeutics |
| بيانات النشر: | Mary Ann Liebert, Inc., publishers, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, genetic structures, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, Connected pen, Endocrinology, Bolus (medicine), Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Dosing, Continuous glucose monitoring, Glycated Hemoglobin, business.industry, Blood Glucose Self-Monitoring, nutritional and metabolic diseases, Original Articles, Middle Aged, medicine.disease, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Anesthesia, Missed bolus dose, Female, business |
| الوصف: | Objective: This study used connected pen to determine missed bolus dose (MBD) frequency during masked and unmasked continuous glucose monitoring (CGM) periods and examined its link with time-in-range (TIR), time-above-range (TAR), time-below-range (TBR), and key participant characteristics in people with diabetes. Methods: This was a 12-week, single-arm, exploratory, two-period study for people with type 1 diabetes (T1D) or type 2 diabetes (T2D). The primary objective was to estimate the average number of MBD during masked and real-time CGM use. The secondary objective was to estimate the average percent TIR and its relationship to MBD. An exploratory objective was to investigate the participant characteristics that were associated with MBD. Data were analyzed for differences in MBD by diabetes type and other participant characteristics, by CGM period, and by hypoglycemic fear scores. Results: Participants (n = 64; T1D, n = 38; T2D, n = 26) were 48 ± 11.9 years old and 44% were female. From the masked to the unmasked period, MBD, %TAR, %TBR, and glycated hemoglobin decreased significantly (0.74 MBD/day to 0.62 MBD/day, P = 0.008; 53.6%–48.1%, P = 0.004; 4.49%–2.93%, P |
| اللغة: | English |
| تدمد: | 1557-8593 1520-9156 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bf5ba04ddb62663930ea2e257d5da67Test http://europepmc.org/articles/PMC8783630Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8bf5ba04ddb62663930ea2e257d5da67 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....8bf5ba04ddb62663930ea2e257d5da67 899 3 unknown 899.047973632813 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8bf5ba04ddb62663930ea2e257d5da67&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Use of Connected Pen as a Diagnostic Tool to Evaluate Missed Bolus Dosing Behavior in People with Type 1 and Type 2 Diabetes
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Howard+Wolpert%22">Howard Wolpert</searchLink><br /><searchLink fieldCode="AR" term="%22Eric+S%2E+Meadows%22">Eric S. Meadows</searchLink><br /><searchLink fieldCode="AR" term="%22Stephanie+Edwards%22">Stephanie Edwards</searchLink><br /><searchLink fieldCode="AR" term="%22Xuanyao+He%22">Xuanyao He</searchLink><br /><searchLink fieldCode="AR" term="%22Wenjie+Wang%22">Wenjie Wang</searchLink><br /><searchLink fieldCode="AR" term="%22Jennal+Johnson%22">Jennal Johnson</searchLink><br /><searchLink fieldCode="AR" term="%22David+Price%22">David Price</searchLink><br /><searchLink fieldCode="AR" term="%22Jiat-Ling+Poon%22">Jiat-Ling Poon</searchLink><br /><searchLink fieldCode="AR" term="%22William+H%2E+Polonsky%22">William H. Polonsky</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Diabetes Technology & Therapeutics ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Mary Ann Liebert, Inc., publishers, 2022. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2022 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Blood+Glucose%22">Blood Glucose</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22genetic+structures%22">genetic structures</searchLink><br /><searchLink fieldCode="DE" term="%22endocrine+system+diseases%22">endocrine system diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Endocrinology%2C+Diabetes+and+Metabolism%22">Endocrinology, Diabetes and Metabolism</searchLink><br /><searchLink fieldCode="DE" term="%22Type+2+diabetes%22">Type 2 diabetes</searchLink><br /><searchLink fieldCode="DE" term="%22Connected+pen%22">Connected pen</searchLink><br /><searchLink fieldCode="DE" term="%22Endocrinology%22">Endocrinology</searchLink><br /><searchLink fieldCode="DE" term="%22Bolus+%28medicine%29%22">Bolus (medicine)</searchLink><br /><searchLink fieldCode="DE" term="%22Diabetes+mellitus%22">Diabetes mellitus</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Hypoglycemic+Agents%22">Hypoglycemic Agents</searchLink><br /><searchLink fieldCode="DE" term="%22Dosing%22">Dosing</searchLink><br /><searchLink fieldCode="DE" term="%22Continuous+glucose+monitoring%22">Continuous glucose monitoring</searchLink><br /><searchLink fieldCode="DE" term="%22Glycated+Hemoglobin%22">Glycated Hemoglobin</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Blood+Glucose+Self-Monitoring%22">Blood Glucose Self-Monitoring</searchLink><br /><searchLink fieldCode="DE" term="%22nutritional+and+metabolic+diseases%22">nutritional and metabolic diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Original+Articles%22">Original Articles</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+Laboratory+Technology%22">Medical Laboratory Technology</searchLink><br /><searchLink fieldCode="DE" term="%22Diabetes+Mellitus%2C+Type+1%22">Diabetes Mellitus, Type 1</searchLink><br /><searchLink fieldCode="DE" term="%22Diabetes+Mellitus%2C+Type+2%22">Diabetes Mellitus, Type 2</searchLink><br /><searchLink fieldCode="DE" term="%22Anesthesia%22">Anesthesia</searchLink><br /><searchLink fieldCode="DE" term="%22Missed+bolus+dose%22">Missed bolus dose</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Objective: This study used connected pen to determine missed bolus dose (MBD) frequency during masked and unmasked continuous glucose monitoring (CGM) periods and examined its link with time-in-range (TIR), time-above-range (TAR), time-below-range (TBR), and key participant characteristics in people with diabetes. Methods: This was a 12-week, single-arm, exploratory, two-period study for people with type 1 diabetes (T1D) or type 2 diabetes (T2D). The primary objective was to estimate the average number of MBD during masked and real-time CGM use. The secondary objective was to estimate the average percent TIR and its relationship to MBD. An exploratory objective was to investigate the participant characteristics that were associated with MBD. Data were analyzed for differences in MBD by diabetes type and other participant characteristics, by CGM period, and by hypoglycemic fear scores. Results: Participants (n = 64; T1D, n = 38; T2D, n = 26) were 48 ± 11.9 years old and 44% were female. From the masked to the unmasked period, MBD, %TAR, %TBR, and glycated hemoglobin decreased significantly (0.74 MBD/day to 0.62 MBD/day, P = 0.008; 53.6%–48.1%, P = 0.004; 4.49%–2.93%, P ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1557-8593<br />1520-9156 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bf5ba04ddb62663930ea2e257d5da67" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bf5ba04ddb62663930ea2e257d5da67</link><br /><link linkTarget="URL" linkTerm="http://europepmc.org/articles/PMC8783630" linkWindow="_blank">http://europepmc.org/articles/PMC8783630</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....8bf5ba04ddb62663930ea2e257d5da67 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 6
[StartPage] => 61
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Adult
[Type] => general
)
[1] => Array
(
[SubjectFull] => Blood Glucose
[Type] => general
)
[2] => Array
(
[SubjectFull] => Male
[Type] => general
)
[3] => Array
(
[SubjectFull] => genetic structures
[Type] => general
)
[4] => Array
(
[SubjectFull] => endocrine system diseases
[Type] => general
)
[5] => Array
(
[SubjectFull] => Endocrinology, Diabetes and Metabolism
[Type] => general
)
[6] => Array
(
[SubjectFull] => Type 2 diabetes
[Type] => general
)
[7] => Array
(
[SubjectFull] => Connected pen
[Type] => general
)
[8] => Array
(
[SubjectFull] => Endocrinology
[Type] => general
)
[9] => Array
(
[SubjectFull] => Bolus (medicine)
[Type] => general
)
[10] => Array
(
[SubjectFull] => Diabetes mellitus
[Type] => general
)
[11] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[12] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[13] => Array
(
[SubjectFull] => Hypoglycemic Agents
[Type] => general
)
[14] => Array
(
[SubjectFull] => Dosing
[Type] => general
)
[15] => Array
(
[SubjectFull] => Continuous glucose monitoring
[Type] => general
)
[16] => Array
(
[SubjectFull] => Glycated Hemoglobin
[Type] => general
)
[17] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[18] => Array
(
[SubjectFull] => Blood Glucose Self-Monitoring
[Type] => general
)
[19] => Array
(
[SubjectFull] => nutritional and metabolic diseases
[Type] => general
)
[20] => Array
(
[SubjectFull] => Original Articles
[Type] => general
)
[21] => Array
(
[SubjectFull] => Middle Aged
[Type] => general
)
[22] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[23] => Array
(
[SubjectFull] => Medical Laboratory Technology
[Type] => general
)
[24] => Array
(
[SubjectFull] => Diabetes Mellitus, Type 1
[Type] => general
)
[25] => Array
(
[SubjectFull] => Diabetes Mellitus, Type 2
[Type] => general
)
[26] => Array
(
[SubjectFull] => Anesthesia
[Type] => general
)
[27] => Array
(
[SubjectFull] => Missed bolus dose
[Type] => general
)
[28] => Array
(
[SubjectFull] => Female
[Type] => general
)
[29] => Array
(
[SubjectFull] => business
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Use of Connected Pen as a Diagnostic Tool to Evaluate Missed Bolus Dosing Behavior in People with Type 1 and Type 2 Diabetes
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Howard Wolpert
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Eric S. Meadows
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Stephanie Edwards
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Xuanyao He
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Wenjie Wang
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jennal Johnson
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => David Price
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jiat-Ling Poon
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => William H. Polonsky
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2022
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 15578593
)
[1] => Array
(
[Type] => issn-print
[Value] => 15209156
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[3] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 24
)
[1] => Array
(
[Type] => issue
[Value] => 1
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Diabetes Technology & Therapeutics
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |